All Articles

A California initiative is betting it can fix employer healthcare by wiring a nonprofit mission into the system's administrative core. Is this the future?

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

Cleveland's Changing Lives Foundation hosts 'An Evening of Impact' to fund its mission of providing immediate, crucial aid to families facing sudden catastrophe.

S&P Global acquires datacenterHawk, signaling a strategic push to map the physical world of AI. The deal highlights the soaring value of data center intelligence.

Without a dime of VC funding, a nurse-owned telepsychiatry practice hit 300k appointments, proving a clinician-first model can thrive.

A new acquisition merges veterinary science with vision-AI, creating a 'digital twin' for pets that analyzes behavior to offer proactive nutritional care.

How one firm's rare feat of achieving both zero injuries and top workplace status for the seventh time offers a powerful lesson in strategic value.

Marion Munley's elevation to AAJ President-Elect isn't just a career milestone; it's a strategic maneuver signaling a more aggressive, specialized fight ahead.

The travel club's Q2 results reveal deep losses and cash burn from its new membership model, testing investor faith amidst geopolitical headwinds.

Korg USA's partnership with Long Island Cares reveals a shift in corporate giving, where hands-on action and leadership are the new keys to success.

As Riot Platforms preps its Q2 earnings call, the real story isn't just Bitcoin. It's a strategic pivot to building the massive infrastructure for our digital future.

A landmark FDA approval allows Walter Reed to 3D-print cranial implants on-site, a strategic shift in military medicine powered by 3D Systems' expertise.

As NAVs fall, Cox Capital expands its discounted tender offers for non-traded BDCs, creating a crucial exit for investors and reshaping the private credit landscape.

A new biotech, CORE Biomedicine, armed with Eisai's preclinical assets and a $21M Series A, aims to upend oncology by targeting cancer's 'lineage' identity.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

Futuri's Content Automation boasts an 80% cut in production time. As AI enters the newsroom, it forces a critical look at the future of journalism itself.

With $21M in funding and a novel 'lineage-based' approach, CORE Biomedicine is moving beyond genomics to target the root cause of cancer's identity.

A new partnership between FordDirect and Dealer Pay is more than a vendor deal. It’s a blueprint for modernizing the car-buying journey for millions.